Carina Biotech to Present Preclinical Data Evaluating LGR5-Targeted CAR-T Cell Therapy in Human Cancer Models at 8th CAR-TCR Summit
21 Aug 2023
Cell TherapyImmunotherapyClinical Study
Carina Biotech to Present Preclinical Data Evaluating LGR5-Targeted CAR-T Cell Therapy in Human Cancer Models at 8th CAR-TCR Summit
LGR5-targeting CAR-T cells effectively kill LGR5-expressing cancerLGR5-expressing cancer cells in in vitro cytotoxicity assays and display significant anti-tumor activity in vivo in a subcutaneous human colorectal cancer xenograft mouse model.
LGR5-targeting CAR-T cells that induce primary tumour clearance confer complete protection against a secondary tumour challenge.
In vivo spatiotemporal distribution and repeated dosing studies demonstrate that LGR5-targeting CAR-T cells do not persist in off-target organs and are safe and well-tolerated under the conditions tested.
These studies allowed selection of a clinical candidate (CNA3103) for a Phase 1/2a clinical trial in patients with advanced colorectal cancer.
ADELAIDE, Australia, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Carina Biotech (Carina), a cell therapy immuno-oncology company, announced a poster presentation from preclinical studies of its LGR5-targeting CAR-T platform in colorectal cancer at the 8th CAR-TCR Summit that will take place in Boston, Massachusetts from 29 August – 1 September 2023.
“We are thrilled to continue to share our preclinical data related to our LRG-5 targeted autologous CAR-T platform in colorectal cancer at the upcoming 8th CAR-TCR Summit,” said Deborah Rathjen, PhD, Carina’s Chief Executive Officer. “We are encouraged by the data evidenced in our preclinical studies, further supporting our LGR5 CAR-T cell candidate, CNA3103. These data were crucial in the selection of CNA3103 for a Phase 1/2a clinical trial in patients with advanced colorectal cancer and we are pleased to report that patient screening has commenced.”
Poster Presentation Details
Title: LGR5-targeting CAR-T cells – The road to the clinic.
Lead Author: Deborah A. Rathjen CEO, Carina Biotech Limited, Adelaide, South Australia,
Session Date and Time: Thursday 31 August 2023 from 3:30 PM ET – 4:30 PM ET
Location: Exhibition Hall D
Poster Board Number: 131
For more information about LGR5 and Carina Biotech’s clinical pipeline visit www.carinabiotech.com.
About Carina Biotech
Immuno-oncology company Carina Biotech is developing CAR-T and other adoptive cell therapies for the treatment of solid cancers. In addition to its LGR5-targeted CAR-T cell therapy CNA3103 for advanced colorectal cancer, CarinaCarina has a deep pipeline of CAR-T programs.
Using its proprietary chemokine receptor platform, CarinaCarina aims to improve traffic to and infiltration of solid cancers by CAR-containing cells, resulting in more potent and specific cancer killing and reduced off-target effects.
Carina also has a fully integrated, proprietary manufacturing process that has both reduced manufacturing time and improved CAR-T cell attributes, capable of delivering robust “serial-killing” CAR-T cells to patients.
For more information please contact:
Deborah Rathjen, PhD
CEO & Managing Director
+61 418 160 425
deborah@carinabiotech.comRudi Michelson
Monsoon Communications
+61 (0)3 9620 3333
rudim@monsoon.com.au Stephanie Carrington
ICR Westwicke
+1 646 277 1282
stephanie.carrington@westwicke.com
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.